Akorn long-term fundamentals remain unchanged, says Leerink Leerink says Akron's long-term fundamentals remain unchanged following the company's FY13 guidance call. The firm thinks management met expectations on the top line, provided a reasonable explanation on margins and slightly disappointed on manufacturing capacity expansion. Leerink raised its price target for Akorn shares to $16 from $14-$15 and keeps an Outperform rating on the name.
Akorn price target raised to $55 from $45 at Piper Jaffray Piper Jaffray raised its price target for Akorn shares to $55 saying approvals of "seemingly minor" abbreviated New Drug Application opportunities, like last week's Phenylephrine Hydrochloride Ophthalmic Solution, could in the aggregate drive significant upside to consensus estimates in 2015 and beyond. Piper reiterates an Overweight rating on shares of Akorn.